
|Videos|February 1, 2017
Safety of Monoclonal Antibodies in Myeloma
Author(s)Keith Stewart, MB, ChB
Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.
Advertisement
Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.
While infusion reactions can occur, pre-medication is recommended. Also, reactions do not usually persist past the first infusion. For daratumumab, these reactions can also affect the upper respiratory system. Also in daratumumab, the agent can affect red cell cross-matching for transfusion. Therefore, all cross-matching should take place before infusions.
To learn more about these treatments, watch
Advertisement
Related Content
Advertisement




First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC
Published: | Updated:

Latest CME
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses
2
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
3
Addressing Financial Toxicity: Team-Based Workflows in Oncology Care
4
Early Amivantamab Experience and Subcutaneous Dosing in COPERNICUS
5












































